A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment
A novel conjugate of docetaxel and biotin (designated as IDD-1010) was designed and chemically synthesized via an ester linkage at position 2’ carbon in docetaxel. The synthesized pure IDD-1010 exhibits a potent anti-cancer activity in in vitro and in vivo studies. At 10 nM, IDD-1010 has induced inc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/3/961 |
| _version_ | 1797486062595997696 |
|---|---|
| author | Mahmoud Rayan Seba Shadafny Adam Falah Mizied Falah Saleh Abu-Lafi Sare Asli Anwar Rayan |
| author_facet | Mahmoud Rayan Seba Shadafny Adam Falah Mizied Falah Saleh Abu-Lafi Sare Asli Anwar Rayan |
| author_sort | Mahmoud Rayan |
| collection | DOAJ |
| description | A novel conjugate of docetaxel and biotin (designated as IDD-1010) was designed and chemically synthesized via an ester linkage at position 2’ carbon in docetaxel. The synthesized pure IDD-1010 exhibits a potent anti-cancer activity in in vitro and in vivo studies. At 10 nM, IDD-1010 has induced increased apoptosis and mitotic arrest of PC3-Luc prostate cancer cells, causing aneuploidy and cell death at higher concentrations. Toxicology studies indicate that the maximal tolerated dose (MTD) of IDD-1010 is 150 mg/kg in mice; equivalent to about 12.2 mg/kg of body weight, or to about an 850 mg dose for a patient weighing 70 kg. The MTD-treated mice exhibited weight gain similar to that of the control group, with no gross pathological signs at 14 days post-dosing. At a lower dose, IDD-1010 treatment did not lead to any significant weight loss in mice, although decreased the tumor volume stemming from injecting cancer cells into the dorsal loop of mouse prostate, and it was found to be more potent than Paclitaxel (reference drug). Similarly, IDD-1010 treatment significantly reduced tumor weight and thereby increased the percentage of mice survival as compared to reference drug-treated and control groups. To summarize, the described experiments using IDD-1010, as compared to the reference drug, strongly suggest a potential treatment utility with a wider therapeutic window for prostate cancer. Henceforth, clinical research on such a novel drug candidate would be greatly worthwhile. |
| first_indexed | 2024-03-09T23:27:50Z |
| format | Article |
| id | doaj.art-f3b112756802485795d99361934a1588 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T23:27:50Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-f3b112756802485795d99361934a15882023-11-23T17:15:19ZengMDPI AGMolecules1420-30492022-01-0127396110.3390/molecules27030961A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer TreatmentMahmoud Rayan0Seba Shadafny1Adam Falah2Mizied Falah3Saleh Abu-Lafi4Sare Asli5Anwar Rayan6Drug Discovery Informatics Lab, QRC-Qasemi Research Center, Al-Qasemi Academic College, Baka EL-Garbiah 30100, IsraelR&D Department, IDD Therapeutics LTD, Nazareth 1711102, IsraelScience Department, York University, Toronto, ON M3J 1P3, CanadaInstitute for Medical Research, Holy Family Hospital, Nazareth 16000, IsraelFaculty of Pharmacy, Al-Quds University, Abu-Dies 144, PalestineThe Institute of Applied Research, Galilee Society, Shefa-Amr 2020, IsraelDrug Discovery Informatics Lab, QRC-Qasemi Research Center, Al-Qasemi Academic College, Baka EL-Garbiah 30100, IsraelA novel conjugate of docetaxel and biotin (designated as IDD-1010) was designed and chemically synthesized via an ester linkage at position 2’ carbon in docetaxel. The synthesized pure IDD-1010 exhibits a potent anti-cancer activity in in vitro and in vivo studies. At 10 nM, IDD-1010 has induced increased apoptosis and mitotic arrest of PC3-Luc prostate cancer cells, causing aneuploidy and cell death at higher concentrations. Toxicology studies indicate that the maximal tolerated dose (MTD) of IDD-1010 is 150 mg/kg in mice; equivalent to about 12.2 mg/kg of body weight, or to about an 850 mg dose for a patient weighing 70 kg. The MTD-treated mice exhibited weight gain similar to that of the control group, with no gross pathological signs at 14 days post-dosing. At a lower dose, IDD-1010 treatment did not lead to any significant weight loss in mice, although decreased the tumor volume stemming from injecting cancer cells into the dorsal loop of mouse prostate, and it was found to be more potent than Paclitaxel (reference drug). Similarly, IDD-1010 treatment significantly reduced tumor weight and thereby increased the percentage of mice survival as compared to reference drug-treated and control groups. To summarize, the described experiments using IDD-1010, as compared to the reference drug, strongly suggest a potential treatment utility with a wider therapeutic window for prostate cancer. Henceforth, clinical research on such a novel drug candidate would be greatly worthwhile.https://www.mdpi.com/1420-3049/27/3/961taxanesdocetaxelpaclitaxelbiotincancer chemotherapyprostate cancer |
| spellingShingle | Mahmoud Rayan Seba Shadafny Adam Falah Mizied Falah Saleh Abu-Lafi Sare Asli Anwar Rayan A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment Molecules taxanes docetaxel paclitaxel biotin cancer chemotherapy prostate cancer |
| title | A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment |
| title_full | A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment |
| title_fullStr | A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment |
| title_full_unstemmed | A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment |
| title_short | A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment |
| title_sort | novel docetaxel biotin chemical conjugate for prostate cancer treatment |
| topic | taxanes docetaxel paclitaxel biotin cancer chemotherapy prostate cancer |
| url | https://www.mdpi.com/1420-3049/27/3/961 |
| work_keys_str_mv | AT mahmoudrayan anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT sebashadafny anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT adamfalah anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT miziedfalah anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT salehabulafi anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT sareasli anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT anwarrayan anoveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT mahmoudrayan noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT sebashadafny noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT adamfalah noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT miziedfalah noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT salehabulafi noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT sareasli noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment AT anwarrayan noveldocetaxelbiotinchemicalconjugateforprostatecancertreatment |